Bond Digital Health has entered into a technology development and commercialisation partnership project with Imspex Diagnostics Ltd.
The two Wales-based specialist life sciences companies will combine their respective technologies – Imspex’s ‘early warning systems’ for healthcare using its proprietary gas chromatography (GC) and Ion Mobility Spectrometry (IMS) technology and Bond’s proprietary Transform® platform, a real-time data capture and management system for diagnostic tests.
Bond’s Commercial Director Phil Groom said: “We’re thrilled to be partnering with Imspex and to be working on an exciting project with a pioneering company.
“We look forward to sharing more information on the partnership and the project early next year.”
Imspex’s Founder and Chairman, Santi Dominguez, said: “This is an exciting project and combines two leading technologies to provide data capture, research and faster diagnosis by clinicians leading to better patient outcomes.”
Imspex Diagnostics Ltd (Imspex) was founded in 2011 and delivers its unique and proprietary combined gas chromatography (GC) and Ion Mobility Spectrometry technologies to deliver fast and accurate detection and diagnosis for a broad range of global industry and healthcare applications. Imspex acquired analytics expert G.A.S. mbH in 2013 and uses its Volatile Organic Compound (VOC) analytical capability to provide quality and contamination solutions for manufacturing and end-products to a range of blue-chip companies and world-leading research hospitals, research centres and universities. The Company continues to expand the boundaries of VOC detection increasing its technology leadership position and capability to develop innovative solutions to an increasing range of industry and healthcare markets requiring speed, accuracy and affordability.
Bond Digital Health Ltd is the only company in the world offering bespoke digital products and services specifically for lateral flow devices. Bond is digitising an entire industry and helping with global efforts to decentralise health testing. Bond has developed a white label digital platform for lateral flow technologies, called Transform®. Featuring app development, cloud data management and a real-time analytics dashboard, Transform® offers secure cloud connectivity and is fully regulated and compliant with medical device software regulations.